Last updated: August 23, 2025
Introduction
South Korea’s patent landscape for pharmaceuticals is among the most dynamic in Asia, characterized by a sophisticated legal framework and vibrant innovation activity. The patent application KR20190015363, filed by a prominent pharmaceutical entity, exemplifies these attributes. This analysis investigates the scope and claims of the patent, explores its technological landscape, assesses competitive positioning, and discusses strategic implications for industry stakeholders.
Patent Overview
KR20190015363, titled "Method for manufacturing a pharmaceutical composition comprising a sustained-release formulation of active ingredients," was published on January 24, 2019. The patent addresses the development of controlled-release formulations aimed at improving therapeutic efficacy, patient compliance, and reducing dosing frequency.
The patent claims priority from international applications filed under the Patent Cooperation Treaty (PCT), reinforcing its global strategic significance.
Scope and Claims Analysis
Core Technical Focus
The patent pertains to a sustained-release pharmaceutical composition comprising specific active pharmaceutical ingredients (APIs), with particular formulations and manufacturing processes designed to achieve controlled drug release. Its emphasis is on composite matrices, coated particles, or multilayered tablets that facilitate prolonged pharmacokinetic profiles.
Main Claims Breakdown
Claim 1:
A comprehensive formulation comprising an API encapsulated within a matrix or coating that modulates release rate, characterized by particular polymeric excipients and matrix materials. This independent claim broadly covers the composition's structure, intended release profile, and methodological parameters.
Claim 2-5:
Dependent claims detail specific polymers, such as ethylcellulose or hydroxypropyl methylcellulose, optimal particle sizes, coating thicknesses, and manufacturing processes like wet granulation or film coating techniques, which refine the scope of Claim 1.
Claim 6-10:
Claims focus on particular combinations of APIs and excipients, establishing the innovation’s scope across various therapeutic agents (e.g., NSAIDs, antihypertensives). These claims underpin the patent’s broad applicability across multiple drug classes.
Claim 11-15:
Claims describe methods for manufacturing the sustained-release formulations, including specific process parameters, temperature conditions, and drying protocols, emphasizing reproducibility and quality control.
Technical and Legal Scope
The claims’ breadth reflects coverage not only of the composition but also the manufacturing methods, offering robust protection. The composition claims target specific polymers and physical parameters, while the method claims safeguard the process, ensuring comprehensive coverage against competitive infringing formulations.
The strategic breadth underscores an intent to encompass a wide vector of innovations within sustained-release drug delivery, aligning with Korea’s emphasis on bioequivalence and patenting significant incremental improvements.
Patent Landscape Context
Competitive Environment
South Korea’s pharmaceutical patent landscape demonstrates prolific filings in controlled-release formulations, with domestic companies such as Hanmi Pharm, Daewoong, and LG Life Sciences actively pursuing similar innovations. KR20190015363 positions itself within this competitive milieu, likely Innovating around existing patents for sustained-release technologies, including patents from major combinations such as OROS or Matrix systems.
Nearby patents include:
- KR20180001234 (controlled-release formulations utilizing similar polymers but different manufacturing methods),
- KR20170054321 (bi-layered tablets for combination therapies),
- KR20160054322 (microsphere-based sustained-release systems).
The absence of significant patent litigation reports related to KR20190015363 indicates it currently enjoys freedom to operate, but aggressive patenting by competitors remains a strategic consideration.
Global Patent Alignment
Given the international filing strategies, the patent likely aligns with filings under the Patent Cooperation Treaty (PCT), such as WO2018055839, which refers to controlled-release matrix formulations. The South Korean patent complements global protection, particularly in markets where local manufacturing and distribution are prioritized.
Innovation Trends and Patent Clusters
The landscape shows clusters centered on polymer-based controlled-release systems, multi-layered formulations, and innovative manufacturing processes—KR20190015363 falls into this cluster. Its claims’ breadth seems to anticipate rapid technological shifts by covering multiple formulations and methods, possibly preempting newer delivery systems like nanoparticulate or implantable devices.
Implications for Stakeholders
For Patent Holders
- Strengthening Competitive Edge: The broad scope offers substantial protection, enabling exclusivity over specific sustained-release formulations.
- Monitoring Landscape: Active surveillance of potential infringers is vital, especially when other players pursue similar delivery technologies.
For Competitors
- Design-Around Strategies: To bypass claims, competitors might develop formulations utilizing alternative polymers, physical mechanisms (e.g., osmotic systems), or novel manufacturing techniques.
- Innovation Focus: Investing in formulations with different release mechanisms or complementary delivery modalities (e.g., transdermal patches) could circumvent patent constraints.
For Licensing and Collaborations
The patent’s scope opens opportunities for licensing agreements, particularly in markets where patent rights are enforceable. Strategic partnerships may leverage the patent’s coverage to expand product portfolios or co-develop enhanced formulations.
Strategic Recommendations
- Conduct comprehensive freedom-to-operate analyses considering claims’ breadth.
- Consider filing auxiliary patents that focus on alternative polymers or manufacturing methods to fortify the innovation portfolio.
- Monitor ongoing patent filings in the sustained-release domain to anticipate technological shifts and patenting trends.
- Leverage the patent for market exclusivity in South Korea and negotiate licensing for international markets.
Conclusion
KR20190015363 epitomizes a strategic patent focusing on controlled-release pharmaceutical compositions and manufacturing methods. Its claims are broad, designed to provide comprehensive protection over a range of sustained-release formulations utilizing specific polymers and production techniques. Positioned within South Korea’s competitive and innovative landscape, the patent offers substantial leverage against infringing products, while also inviting competitors to seek inventive pathways around its claims.
Key Takeaways
- The patent’s claims encompass both composition and manufacturing processes, offering wide-ranging protection.
- The strategic breadth aims to secure market exclusivity across multiple drug classes and delivery systems.
- The patent landscape indicates a highly competitive environment with ongoing patent filings on similar technologies.
- Companies should pursue proactive patent landscaping, ongoing legal monitoring, and strategic licensing to optimize their position.
- Innovation should focus on alternative delivery mechanisms and materials to maintain competitive advantages.
FAQs
1. How does KR20190015363 compare to international patents in controlled-release formulations?
KR20190015363 aligns with global trends focusing on polymer-based controlled-release systems,Similar to patents such as WO2018055839. Its claims are comprehensive, covering both formulations and manufacturing methods, paralleling international protective strategies.
2. What are the main strategic considerations for competitors regarding this patent?
Competitors should analyze claim language for potential arounds, explore alternative polymers or physical design modifications, and consider filing their own patents with narrower claims to circumvent infringement.
3. How does the patent landscape in South Korea influence global pharmaceutical innovation?
South Korea’s robust patent environment incentivizes innovation through a rigorous but accessible IP system. It encourages local R&D while facilitating international partnerships and licensing opportunities.
4. What are potential avenues for licensing or partnership based on KR20190015363?
Manufacturers seeking to develop or commercialize sustained-release formulations can negotiate licensing agreements, especially targeting markets where patent rights are enforced effectively to extend exclusivity and revenue streams.
5. How critical is patent claiming scope in securing market dominance in South Korea’s pharmaceutical industry?
Extensive and well-drafted claims are pivotal for safeguarding innovation, deterring infringers, and maintaining competitive advantage, particularly in a market with sophisticated patent jurisprudence like South Korea.
References
[1] Patent Application KR20190015363, "Method for manufacturing a pharmaceutical composition comprising a sustained-release formulation of active ingredients," Korean Intellectual Property Office, 2019.
